Turbine, founded in 2016 and headquartered in Hungary, is revolutionizing drug discovery through the virtualization of biological experiments using AI. Positioned at the intersection of AI, Biopharma, and Biotechnology, Turbine's mission is to enhance the clinical translatability of drug discovery processes.
By constructing virtual disease models, Turbine aims to refine the predictive capabilities for drug responses, positioning these simulations just shy of real patient outcomes. Their technology facilitates pharma companies in optimizing therapeutic ideas by eliminating years of unproductive research and minimizing Phase II trial failures due to efficacy issues.
Backing their claims of efficacy, Turbine has nearly 30 research collaborations with industry leaders like Bayer and AstraZeneca. The company's latest venture round, secured on May 16, 2024, led by Accenture Ventures, speaks to investor confidence. Supported by Accel and MSD Global Health Innovation Fund, Turbine remains committed to equipping scientists with their proprietary predictive simulations across pipelines.